NasdaqCM - Delayed Quote USD

Genenta Science S.p.A. (GNTA)

Compare
3.9220 -0.0780 (-1.95%)
At close: September 27 at 4:00 PM EDT
Loading Chart for GNTA
DELL
  • Previous Close 4.0000
  • Open 4.1300
  • Bid --
  • Ask --
  • Day's Range 3.9220 - 4.4100
  • 52 Week Range 2.2000 - 5.8700
  • Volume 8,763
  • Avg. Volume 13,341
  • Market Cap (intraday) 71.447M
  • Beta (5Y Monthly) 0.77
  • PE Ratio (TTM) --
  • EPS (TTM) -0.7100
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

www.genenta.com

14

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GNTA

View More

Performance Overview: GNTA

Trailing total returns as of 9/28/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

GNTA
20.77%
MSCI WORLD
17.59%

1-Year Return

GNTA
31.07%
MSCI WORLD
31.19%

3-Year Return

GNTA
60.98%
MSCI WORLD
17.38%

5-Year Return

GNTA
60.98%
MSCI WORLD
17.38%

Compare To: GNTA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GNTA

View More

Valuation Measures

Annual
As of 9/27/2024
  • Market Cap

    71.45M

  • Enterprise Value

    50.46M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.14

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -26.29%

  • Return on Equity (ttm)

    -45.16%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -11.65M

  • Diluted EPS (ttm)

    -0.7100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    18.78M

  • Total Debt/Equity (mrq)

    0.13%

  • Levered Free Cash Flow (ttm)

    -7.58M

Research Analysis: GNTA

View More

Company Insights: GNTA

Research Reports: GNTA

View More

People Also Watch